The International Contrast Ultrasound Society (ICUS)
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., has announced that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
LUMASON, known globally as SonoVue®, was approved by the FDA ion October 2014 for use in adults with suboptimal echocardiograms. LUMASON is now the first ultrasound contrast agent to obtain FDA approval for use in liver imaging, to improve the sensitivity and specificity of ultrasonography for the differentiation between malignant and benign focal hepatic lesions. This approval also makes LUMASON the first ultrasound contrast agent approved for use in the pediatric population.
Click here for ICUS media release.